New Investigator Clinical Trials Course Faculty Dr. Wyatt is an assistant professor in Urologic Sciences at the University of British Columbia, Canada. He is also cross-appointed at the Vancouver Prostate Centre and BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His primary research goals are to identify associations between molecular alterations in metastatic genitourinary cancers and clinical outcomes, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response. Dr. Wyatt is the chair of correlative sciences for genitourinary cancer trials run through the Canadian Cancer Trial Group (CCTG). He also serves as a member of the investigational new drug program executive committee. Dr. Wyatt directs the ctDNA screening strategy and the molecular tumor board for the first multi-center phase 2 umbrella trial in metastatic castration-resistant prostate cancer (NCT03385655, NCT02905318).
